Would benzonatate 100 mg three times daily be more appropriate for treating an acute cough than continuing the triple inhaler therapy (fluticasone furoate/umeclidinium/vilanterol)?

Benzonatate is NOT Appropriate for Acute Cough - Continue Triple Therapy if Indicated

For acute cough, benzonatate 100 mg TID should NOT be routinely prescribed, as it has no proven benefit and may cause harm. The most recent high-quality evidence from 2020 explicitly recommends against routine use of antitussives for acute bronchitis 1, and a 2025 prospective cohort study found benzonatate provided no benefit for duration or severity of cough despite being commonly prescribed 2.

Key Clinical Decision Points

If This is Acute Bronchitis/Upper Respiratory Infection:

• Do not prescribe benzonatate - The 2020 CHEST guidelines explicitly recommend against routine prescription of antitussives for acute bronchitis in immunocompetent adults 1
• Benzonatate is FDA-approved for symptomatic cough relief 3, but real-world evidence shows it doesn't work: the 2025 JGIM study found no association between benzonatate and reduced cough duration, severity, or need for follow-up visits 2
• The 2006 ACCP guidelines confirm that peripheral cough suppressants (benzonatate's class) have "limited efficacy" for URI and are Grade D recommendation (not recommended) 4

Regarding the Triple Inhaler (FF/UMEC/VI):

If the patient has asthma with persistent cough:

• Continue the triple therapy - A 2025 randomized controlled trial specifically demonstrated FF/UMEC/VI significantly improved cough symptoms in asthma patients with persistent cough (p=0.006) with early response within 6 weeks 5
• The triple therapy also improved asthma control scores and lung function without significant adverse events 5

If the patient has COPD:

• Continue the triple therapy - Real-world evidence from 2026 shows FF/UMEC/VI is well-tolerated and effective, with low cardiovascular event rates 6
• The 2020 guidelines note that exacerbations of chronic airways diseases (COPD, asthma) may require different therapeutic management and should be considered as differential diagnoses 1

If this is truly acute bronchitis without underlying chronic lung disease:

• Discontinue the triple therapy - The 2020 CHEST guidelines recommend against routine use of inhaled beta agonists, inhaled anticholinergics, or inhaled corticosteroids for acute bronchitis 1
• Triple therapy is not indicated for simple acute bronchitis

Critical Pitfalls to Avoid

1. Don't confuse acute bronchitis with COPD/asthma exacerbation - The guidelines emphasize that conditions mimicking acute bronchitis (asthma exacerbations, COPD exacerbations) require different management 1. If the patient has underlying chronic lung disease, the triple therapy is appropriate.

2. Benzonatate has known harms without proven benefit - The 2025 study explicitly states benzonatate has "no evidence of benefit and well-known harms" yet was commonly prescribed 2. Don't add it.

3. Reassess if cough persists or worsens - If acute bronchitis worsens, consider bacterial superinfection or alternative diagnoses rather than adding symptomatic medications 1

The Bottom Line

The answer depends entirely on the underlying diagnosis:

• Acute bronchitis alone: Stop triple therapy, don't add benzonatate
• Asthma with persistent cough: Continue triple therapy (proven effective 5), don't add benzonatate
• COPD: Continue triple therapy, don't add benzonatate

The evidence is clear that benzonatate should not be prescribed for acute cough regardless of the scenario 1, 2.